These findings reveal that TRIM40 drives cardiac hypertrophy through K63-linked ubiquitination and activation of PKN2, identifying TRIM40 as a promising candidate for therapeutic intervention in HF. The gene discussed is PKN2; the disease is cardiac hypertrophy.